SATO VICKI L 4

What Happened

• Vicki L. Sato, a director of Vir Biotechnology, sold 22,000 shares in an open-market sale on April 1, 2026. The weighted average sale price was $9.07 per share, producing gross proceeds of approximately $199,617. This was a sale (not a purchase), which is generally viewed as routine insider liquidity rather than a direct bullish signal.

Key Details

• Transaction date: 2026-04-01; filed on Form 4 on 2026-04-02 (timely — reported within the typical two-business-day window).
• Shares sold: 22,000; weighted average price: $9.07; price range across multiple trades: $8.87 to $9.20.
• Proceeds: ~ $199,617.
• Shares owned after transaction: not specified in the provided filing summary.
• Footnotes: (F1) Sales were executed under a Rule 10b5-1 trading plan adopted March 27, 2025. (F2) The reported price is a weighted average; the reporting person can provide per-trade prices on request.
• Transaction type/code: S = sale (open-market or private sale).

Context

• A 10b5-1 plan means the trades were prearranged and can indicate planned, rule-compliant selling rather than opportunistic timing. Sales are common for insiders for diversification or personal-liquidity needs; they do not on their own prove a view on company prospects.
• For retail investors, purchases typically carry more informational weight than routine sales; consider this sale alongside other insider activity and company fundamentals.